These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 12647220)

  • 1. Expression patterns of transcription factors in progressively transformed germinal centers and Hodgkin lymphoma.
    Steimle-Grauer SA; Tinguely M; Seada L; Fellbaum C; Hansmann ML
    Virchows Arch; 2003 Mar; 442(3):284-93. PubMed ID: 12647220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B-cell transcription factors Pax-5, Oct-2, BOB.1, Bcl-6, and MUM1 are useful markers for the diagnosis of nodular lymphocyte predominant Hodgkin lymphoma.
    Herbeck R; Teodorescu Brînzeu D; Giubelan M; Lazăr E; Dema A; Ioniţă H
    Rom J Morphol Embryol; 2011; 52(1):69-74. PubMed ID: 21424034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma.
    Browne P; Petrosyan K; Hernandez A; Chan JA
    Am J Clin Pathol; 2003 Nov; 120(5):767-77. PubMed ID: 14608905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
    Moore EM; Swerdlow SH; Gibson SE
    Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of fascin and JunB in distinguishing nodular lymphocyte predominant from classical lymphocyte-rich Hodgkin lymphoma.
    Bhargava P; Pantanowitz L; Pinkus GS; Pinkus JL; Paessler ME; Roullet M; Gautam S; Bagg A; Kadin ME
    Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):16-23. PubMed ID: 19550297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of transcription factor OCT.1, OCT.2 and BOB.1 expression using tissue arrays in classical Hodgkin's lymphoma.
    García-Cosío M; Santón A; Martín P; Camarasa N; Montalbán C; García JF; Bellas C
    Mod Pathol; 2004 Dec; 17(12):1531-8. PubMed ID: 15257313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential expression patterns of c-REL protein in classic and nodular lymphocyte predominant Hodgkin lymphoma.
    Xiao Q; Shen N; Hedvat CV; Moskowitz CH; Sussman LK; Filippa DA; Zelenetz AD; Houldsworth J; Chaganti RS; Teruya-Feldstein J
    Appl Immunohistochem Mol Morphol; 2004 Sep; 12(3):211-5. PubMed ID: 15551733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential Emu enhancer activity and expression of BOB.1/OBF.1, Oct2, PU.1, and immunoglobulin in reactive B-cell populations, B-cell non-Hodgkin lymphomas, and Hodgkin lymphomas.
    Loddenkemper C; Anagnostopoulos I; Hummel M; Jöhrens-Leder K; Foss HD; Jundt F; Wirth T; Dörken B; Stein H
    J Pathol; 2004 Jan; 202(1):60-9. PubMed ID: 14694522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-positive CD4+CD8+ T-cell population is commonly found in nodular lymphocyte predominant Hodgkin lymphoma.
    Rahemtullah A; Reichard KK; Preffer FI; Harris NL; Hasserjian RP
    Am J Clin Pathol; 2006 Nov; 126(5):805-14. PubMed ID: 17050078
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between lymphocyte immunophenotypes and histologic subtypes of Hodgkin's lymphoma and its significance].
    Zhang Y; Li XZ; Wen ZH; Chen XY; Zhang G; Wang X; Wu ZQ; Zhao T
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Aug; 17(4):888-93. PubMed ID: 19698223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraparotid classical and nodular lymphocyte-predominant Hodgkin lymphoma: pattern analysis with emphasis on associated lymphadenoma-like proliferations.
    Agaimy A; Wild V; Märkl B; Wachter DL; Hartmann A; Rosenwald A; Ihrler S
    Am J Surg Pathol; 2015 Sep; 39(9):1206-12. PubMed ID: 25929348
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphocyte-rich classical Hodgkin lymphoma (LRCHL): clinico-pathological characteristics and outcome of a rare entity.
    de Jong D; Bosq J; MacLennan KA; Diebold J; Audouin J; Chasle J; Mandard AM; Marnay J; Henry-Amar M; ;
    Ann Oncol; 2006 Jan; 17(1):141-5. PubMed ID: 16284059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metallothionein as a useful marker in Hodgkin lymphoma subclassification.
    Penkowa M; Sørensen BL; Nielsen SL; Hansen PB
    Leuk Lymphoma; 2009 Feb; 50(2):200-10. PubMed ID: 19199157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
    Gerber NK; Atoria CL; Elkin EB; Yahalom J
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization and Purification of Neoplastic Cells of Nodular Lymphocyte Predominant Hodgkin Lymphoma from Lymph Nodes by Flow Cytometry and Flow Cytometric Cell Sorting.
    Fromm JR; Thomas A; Wood BL
    Am J Pathol; 2017 Feb; 187(2):304-317. PubMed ID: 27998726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma.
    Wlodarska I; Nooyen P; Maes B; Martin-Subero JI; Siebert R; Pauwels P; De Wolf-Peeters C; Hagemeijer A
    Blood; 2003 Jan; 101(2):706-10. PubMed ID: 12393409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression and significance of B-cell-specific activator protein of H/RS cell in classical Hodgkin's Lymphoma].
    Zhou X; Zhao T; Qi Z; Liu G; Zhu M
    Zhonghua Yi Xue Za Zhi; 2002 Nov; 82(22):1532-5. PubMed ID: 12609061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hodgkin-like anaplastic large cell lymphoma (previously designated in the REAL classification) has same immunophenotypic features to classical Hodgkin lymphoma.
    Tamaru J; Tokuhira M; Nittsu N; Nakamura S; Ichinohasama R; Suzuki R; Mori H; Takagi T; Suzuki T; Itami J; Itoyama S; Mikata A
    Leuk Lymphoma; 2007 Jun; 48(6):1127-38. PubMed ID: 17577776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactive T cells by flow cytometry distinguish Hodgkin lymphomas from T cell/histiocyte-rich large B cell lymphoma.
    Wu D; Thomas A; Fromm JR
    Cytometry B Clin Cytom; 2016 Sep; 90(5):424-32. PubMed ID: 26084540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of an expanded immunohistochemical panel to distinguish cutaneous Hodgkin lymphoma from histopathologic imitators.
    Cho RJ; McCalmont TH; Ai WZ; Fox LP; Treseler P; Pincus LB
    J Cutan Pathol; 2012 Jun; 39(6):651-8. PubMed ID: 22324490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.